Core Viewpoint - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing a rally, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, gaining over 2% and surpassing the 60-day moving average [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and rose by 2.02%, reaching a price of 0.555 [2]. - Major components of the ETF, such as InnoCare Pharma-B and Hutchison China MediTech, saw significant gains of over 6% and 4%, respectively [1][3]. Group 2: Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin original and generic drugs in China [1][3]. Group 3: Company Developments - Recent announcements from innovative drug companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Rilapladib by Hengrui Medicine [3]. - Securities firms are increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and effectively controls risks associated with less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 73% of its weight, highlighting the dominance of leading innovative drug companies [5].

Group 1 - The core viewpoint of the news highlights significant achievements in the innovation drug sector, with a record 76 innovative drugs expected to be approved for market in China by 2025, marking a historical high [1] - The healthcare payment system is continuously optimized, with the introduction of a "commercial insurance innovative drug directory" mechanism, which enhances the payment capacity for innovative drugs through the complementary combination of medical insurance and commercial insurance [1] - Institutions are optimistic about the pharmaceutical and biotechnology industry, with Donghai Securities predicting that China will officially enter a new era of innovative drugs by 2026 [1] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks including WuXi Biologics, Innovent Biologics, BeiGene, and others, accounting for over 71.80% of the total weight [2] - The management and custody fees for the Harvest Hong Kong Stock Connect Innovative Drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term allocation tool and professional investors for flexible trading needs [2]

Core Viewpoint - The Hong Kong stock market continues to adjust, but innovative pharmaceuticals are leading the gains, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, surpassing the 60-day moving average [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and increased by 2%, with a notable performance from its constituent stocks, including Immune-Oncotherapy (up over 6%) and Hutchison China MediTech (up over 4%) [1]. - The ETF's net asset value has shown a significant increase, reflecting strong investor interest in the innovative drug sector [2]. Group 2: Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin innovative and generic drugs in China [1][3]. Group 3: Company Developments - Recent announcements from innovative pharmaceutical companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Rilapladib by Hengrui Medicine [3]. - Securities firms have been increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drug companies, has a high concentration of leading firms, and employs measures to control risks associated with less liquid stocks [4][5]. - The top ten constituent stocks of the ETF account for over 73% of its weight, indicating a strong representation of leading companies in the innovative drug sector [6].

Group 1 - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing gains, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, up 2% and surpassing the 60-day moving average [1][8] - Major components of the ETF include companies like InnoCare Pharma-B, which rose over 6%, and Hutchison China MediTech, which increased by over 4% [1][8] - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin drugs and generics in China [1][10] Group 2 - Recent announcements from innovative drug companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Ruilafup α injection by Hengrui Medicine [3][10] - Securities firms are increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3][10] - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and offers better risk control by reducing the weight of less liquid stocks [3][10] Group 3 - The top ten holdings in the Hong Kong Stock Connect Innovative Drug ETF account for over 73% of the total weight, indicating a strong presence of leading companies in the innovative drug sector [4][11] - Notable companies in the ETF include Kangfang Biologics (10.49% weight), BeiGene (10.01%), and CSPC Pharmaceutical Group (9.97%), among others, with a total market capitalization of approximately HKD 11.35 billion [4][11] - For investors looking to reduce volatility while still focusing on innovative drugs, the market offers the only pharmaceutical ETF (562050) that combines innovative drugs with traditional Chinese medicine, providing a more stable investment option [4][12]

Core Viewpoint - The Hong Kong stock market for innovative drugs has experienced a rally since the beginning of 2026, driven by positive clinical data from Arrowhead, which has boosted sentiment in the sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has shown strong performance, with a nearly 2% increase and a trading volume exceeding 9 billion, indicating high trading activity [6]. - As of January 7, 2026, the ETF's latest scale has surpassed 24.7 billion, leading its peers in the same category [6]. - The majority of the weighted stocks in the ETF index have shown positive performance, with notable increases from companies like Sanofi and Innovent Biologics [2]. Group 2: Company News - Strong Brain Technology, a brain-computer interface "unicorn," has completed a financing round of 2 billion, second only to Musk's Neuralink [1]. - Insilico Medicine, an AI-driven pharmaceutical company, has announced a long-term collaboration with Sihuan Pharmaceutical for anti-tumor drug development, with a total cooperation amount of 888 million [1]. Group 3: Industry Trends - The innovative drug industry is expected to continue its upward trend, with catalysts on the horizon. The market anticipates a busy period for business development (BD) transactions and data disclosures in early 2026 [4]. - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 global participants, showcasing advancements in biotechnology, pharmaceuticals, and medical devices [5]. - Three major trends are emerging in the industry: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the rise of emerging market players [7]. Group 4: Investment Insights - The average total package for top multinational corporations (MNCs) purchasing innovative drugs or technology platforms from China in 2025 is 2.756 billion, indicating a willingness to pay higher prices for Chinese innovations [8]. - The focus of MNCs is shifting from merely acquiring products to obtaining platforms and time, emphasizing the importance of technology platforms that can produce new molecules [10]. - Investment logic suggests that MNCs are willing to pay premiums for clinically validated assets, particularly those that can fill pipeline gaps and provide immediate revenue [11].

Group 1 - The overall market sentiment for innovative drug overseas BD transactions has shifted from extreme optimism to a more rational understanding, leading to significant stock price declines for many small companies in the A-share and H-share markets [1] - The driving logic for the innovative drug industry in 2026 will rely on tangible overseas clinical advancements and increased certainty in overseas commercialization, moving away from transient BD transactions [1] - Major companies in the innovative drug sector, including industry leaders and quality second-tier companies, are beginning to stabilize and show upward trends in stock prices [1] Group 2 - Two significant oncology drugs, AK112 from Kangfang Biotech and SKB264 from Kelun-Biotech, are expected to have major impacts in their respective fields, with ongoing clinical trials and potential breakthroughs [3] - Kangfang Biotech's AK112 has seen a series of clinical advancements that have sparked global interest in second-generation IO development, leading to multiple impactful BD transactions [3] - SKB264 is positioned as a potential global first-in-class drug in the ADC category, with ongoing clinical trials and a significant focus on its efficacy in various cancers [5] Group 3 - Kangfang Biotech is expected to read out three major Phase III clinical results in 2026, including two first-line lung cancer trials, with potential approval timelines set for 2025 and 2027 [4] - Kelun-Biotech's SKB264 is anticipated to read out important clinical results for two major indications in 2026, which could validate its market potential outside of China [7] - The innovative drug industry is expected to see significant clinical progress from various companies that have engaged in substantial BD transactions in 2024-2025, enhancing the long-term value of their overseas projects [7][9]

Group 1 - The Hong Kong innovation drug sector has recorded a three-day consecutive rise since the beginning of 2026, with a rebound of approximately 10% in the main innovation drug index [1][8] - The Hong Kong Innovation Drug ETF (520880) has accumulated a gain of 9.24% since the start of the year, with a notable increase of over 3.4% on January 7 [1][8] - In 2025, the innovation drug sector represented by Hong Kong stocks saw an overall increase of over 60%, becoming a significant player in the market [3][11] Group 2 - The surge in the innovation drug sector at the beginning of 2025 is attributed to multiple catalysts, including favorable policies, better-than-expected industry data, and the approach of important industry conferences [5][13] - Significant developments include the approval of the first domestically produced CTLA-4 inhibitor "Daboshu" by Innovent Biologics and the approval of TROP2 ADC "Dercutuzumab" for breast cancer by AstraZeneca and Daiichi Sankyo, enhancing the ADC sector's competitive edge [5][13] - The total amount of outbound licensing for Chinese innovative drugs reached $135.655 billion in 2025, with 157 transactions, both setting historical records [5][13] Group 3 - The sector's valuation is currently at a relatively low level following previous adjustments, and there has been a noticeable inflow of funds driven by strong fundamental data [6][14] - Investment outlook for 2026 focuses on innovation and international expansion, with an emphasis on companies that have achieved significant business development (BD) transactions and those with unexpected overseas clinical progress [6][14] - The industry is entering a "dual-driven" 3.0 era of product development and commercial sales, with a clear upward trend in demand for next-generation therapies such as ADCs and dual antibodies [6][14] Group 4 - New technologies such as AI in drug development and brain-computer interfaces are expected to accelerate industrialization due to supportive policies and pricing [7][15] - Areas facing potential recovery include medical device exports, consumer healthcare, and OTC traditional Chinese medicine, which may present wave-like investment opportunities under improving policies or macroeconomic conditions [7][15] - The investment logic in the pharmaceutical sector for 2026 has shifted from broad-based gains to selective alpha strategies, favoring companies with robust technology and clear commercialization paths [7][15]

行业多项关键政策突破与落地，首版《商业健康保险创新药品目录》于2025年12月正式发布，其构建 的"基本医保保基本，商保保创新"的多层次支付体系，为高值创新药开辟出市场新通路。 展望2026年，业内人士普遍看好，在产业政策对真创新、高水平创新的支持下，大量创新药BD将密集 落地。 商保实施与集采优化双轮推动下，创新药产业链高景气度有望延续，高价值创新药有望迎来第二增长曲 线。 港股创新药板块企业包括： 智通财经APP获悉，记者从国家药监局获悉，为加快临床急需境外已上市药品在境内上市，满足患者临 床用药迫切需求，国家药监局进一步优化这类药品审评审批。国家药监局表示，坚持以临床价值为导 向，鼓励申请人在中国开展全球同步研发、同步申报上市;鼓励临床急需境外已上市的原研药及仿制药 在境内申报，对于符合要求的可纳入优先审评审批范围。 公告显示，国家药监局将优化审评机制，加快审评速度;同时，也将完善检验制度，体现品种特点。 2025年我国已批准上市的创新药达76个，大幅超过2024年全年48个，创历史新高。此外，2025年我国创 新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，同样创历史新高。 据了解 ...

Core Viewpoint - The National Medical Products Administration (NMPA) is optimizing the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients in China [1][2]. Group 1: Regulatory Changes - The NMPA will enhance the review mechanism and accelerate the review speed while improving the inspection system to reflect the characteristics of various drug types [2]. - The NMPA encourages applicants to conduct global synchronous research and simultaneous application for market approval in China for urgently needed foreign drugs [1]. Group 2: Market Performance - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024 [2]. - The total amount of authorized transactions for innovative drugs in 2025 exceeded $130 billion, with over 150 transactions, marking another historical high [2]. Group 3: Drug Composition - The 76 innovative drugs approved in 2025 include 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [2]. - Among the 47 chemical drugs, 38 are domestic innovations, and 9 are imported, with domestic innovations accounting for 80.85% [2]. - For the 23 biological products, 21 are domestic innovations, and 2 are imported, with domestic innovations making up 91.30% [2]. Group 4: Industry Outlook - The release of the first version of the "Commercial Health Insurance Innovative Drug Directory" in December 2025 establishes a multi-layered payment system, creating new market pathways for high-value innovative drugs [2]. - Industry insiders are optimistic about 2026, anticipating a surge in innovative drug business development (BD) due to supportive industrial policies for true and high-level innovations [2]. - The dual push from commercial insurance implementation and procurement optimization is expected to sustain high prosperity in the innovative drug industry, with high-value innovative drugs likely to experience a second growth curve [2]. Group 5: Key Companies - Notable companies in the Hong Kong innovative drug sector include: Heng Rui Medicine, Kelun-Botai Biological, and others [3]. - Leading companies in the CXO sector include: Kailai Ying, Kanglong Chemical, and others [4].

Core Viewpoint - The Hong Kong biopharmaceutical sector experienced a significant surge on January 7, with multiple stocks showing substantial gains, driven by positive clinical data from Arrowhead's small RNA drug [1][2]. Group 1: Market Performance - On January 7, stocks such as Rongchang Biopharmaceutical, China Antibody, and Chuangsheng Group saw increases of 12.93%, 11.97%, and 11.57% respectively, with nearly 40 stocks rising over 5% [1]. - Over the first four trading days of the year, the Hong Kong innovative drug sector has shown a notable rally, with Zhongsheng Beikong Biotech and Zhongzhi Pharmaceutical achieving cumulative increases of 49.12% and 42.85% respectively [1]. - Other companies like Jiasheng Health, Rongchang Biopharmaceutical, and Saintno Pharmaceutical also reported cumulative gains exceeding 20%, while over 40 stocks, including Tigermed and China Antibody, saw increases of over 10% [1]. Group 2: Catalyst for Growth - A broker analyst indicated that the surge on January 7 was primarily stimulated by Arrowhead's favorable clinical data for its small RNA drug, which positively influenced the sentiment in the innovative drug sector [1]. - The small RNA drug sector is viewed as transitioning from concept validation to a phase of industrial emergence, with expectations for new molecules to enter clinical trials in China by 2026-2027 [2]. Group 3: Upcoming Events - The upcoming J.P. Morgan Annual Healthcare Conference, scheduled for January 12-15 in San Francisco, is anticipated to serve as a catalyst for the innovative drug market, with several Hong Kong companies confirming participation [3].